Is Highwoods Properties (HIW) Using Sustainability-Linked Debt to Quietly Redefine Its Risk Profile?

• In early June 2026, Highwoods Properties, Inc. recast a US$150,000,000 unsecured bank term loan, extending its maturity from May 2027 to June 2031 and resetting interest to SOFR plus 90 basis points, alongside updated pricing on a US$200,000,000 term loan and a US$750,000,000 unsecured revolving credit facility with sustainability-linked rate adjustments.
• This refinancing not only smooths Highwoods’ debt maturity schedule but also ties a portion of its borrowing costs to measurable greenhouse gas emissions reductions, underscoring how lenders are increasingly linking capital access to environmental performance.
• We’ll now assess how Highwoods’ extended debt maturity and sustainability-linked interest rates affect its existing investment narrative and risk profile.

We've uncovered the 8 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.

Highwoods Properties Investment Narrative Recap

To own Highwoods, you need to be comfortable with a Sunbelt office REIT story that leans on leasing momentum, Class A assets and disciplined capital management. The latest US$150,000,000 term loan recast to 2031 looks incremental rather than transformational, but it modestly reduces near term refinancing risk while leaving the main tension intact between embedded leasing upside and pressure from weaker earnings and tight interest coverage.

The most relevant recent announcement alongside this refinancing is the board’s decision in April 2026 to maintain the US$0.50 quarterly common dividend and authorize up to US$250,000,000 of share repurchases. Together with extended debt maturities and sustainability linked pricing, this frames a capital allocation story where management is balancing reinvestment, balance sheet resilience and shareholder distributions against declining earnings and low forecast returns on equity.

Yet investors should be aware that the combination of declining earnings, high payout commitments and interest coverage pressure could...

Read the full narrative on Highwoods Properties (it's free!)

Highwoods Properties' narrative projects $921.8 million revenue and $91.9 million earnings by 2029. This requires 4.5% yearly revenue growth and an earnings decrease of $65.4 million from $157.3 million today.

Uncover how Highwoods Properties' forecasts yield a $26.22 fair value, a 12% downside to its current price.

Exploring Other Perspectives

Some of the most optimistic analysts were expecting roughly US$913.9 million of revenue and US$97.0 million of earnings by 2029, which contrasts sharply with balance sheet concerns and suggests this new refinancing could either reinforce their confidence or prompt a rethink depending on how you weigh the added maturity runway against the risk of persistently weak interest cover.

Explore 3 other fair value estimates on Highwoods Properties - why the stock might be worth over 2x more than the current price!

Reach Your Own Conclusion

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your Highwoods Properties research is our analysis highlighting 2 key rewards and 4 important warning signs that could impact your investment decision.
• Our free Highwoods Properties research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Highwoods Properties' overall financial health at a glance.

Interested In Other Possibilities?

Early movers are already taking notice. See the stocks they're targeting before they've flown the coop:

• Uncover the next big thing with 24 elite penny stocks that balance risk and reward.
• Explore 29 top quantum computing companies leading the revolution in next-gen technology and shaping the future with breakthroughs in quantum algorithms, superconducting qubits, and cutting-edge research.
• AI is about to change healthcare. These 40 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.